Introduction {#s0005}
============

The metabolic syndrome (MetS) comprises a combination of interconnected physiological, biochemical, clinical, and metabolic factors that predispose for cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), and increased all-cause mortality ([@bb0395]). Many definitions of MetS have been proposed, with the most recent comprising five equal criteria: elevated waist circumference (WC; within population-specific criteria), elevated triglyceride (TG) levels, elevated fasting glucose, low high-density lipoprotein cholesterol (HDL-C) levels, and elevated blood pressure (BP; [@bb0030]). The presence of at least three of these criteria is necessary and sufficient for a diagnosis of MetS.

There has been ongoing interest in comorbidities, such as skin disease, associated with MetS and the mechanisms that underlie these associations. Any pathophysiologic dysfunction, such as insulin resistance (IR), that results in metabolic alterations can also result in cutaneous disease ([@bb0720], [@bb0825]). A body of literature has demonstrated that sex hormones are linked to pathways of MetS ([@bb0010], [@bb0450], [@bb0460], [@bb0645]). Obesity induces chronic inflammation associated with MetS, and the bidirectional relationship of sex hormones with obesity has been validated in several studies ([@bb4600]). The relationships between sex hormones and MetS are illustrated in [Figure 1](#fig0005){ref-type="fig"}. The main pathophysiologic mechanisms that underlie the link between MetS and skin disease are presented in [Table 1](#tbl0005){ref-type="table"}. Herein, we describe sex hormone--mediated or --affected skin diseases associated with MetS and elaborate on associations with components of MetS.Fig. 1Relationships between sex hormones and metabolic syndrome in women. ER, estrogen receptor; HRT, hormone replacement therapy; SHBG, sex hormone-binding globulin; T, testosterone. Solid arrows indicate a triggering effect on metabolic syndrome; dotted arrow indicates an inhibitory/preventive effect.Fig. 1Table 1Main mechanisms of metabolic syndrome in women with skin diseaseTable 1Main mechanismsConditionHyperandrogenism + insulin resistancePolycystic ovary syndromeInsulin resistanceAcanthosis nigricans\
Acne vulgarisPotential insulin resistanceAcrochordons\
Pattern alopecia\
Systemic lupus erythematosusChronic inflammation + insulin resistanceHidradenitis suppurativa\
Psoriasis vulgarisChronic inflammationLichen planusUnknownAtopic dermatitis\
Squamous cell carcinoma Seborrheic dermatitis

Animal studies on sex hormones and metabolic syndrome {#s0010}
=====================================================

Developmental exposure to excess testosterone (T) causes neuroendocrine, ovarian, and metabolic deficits ([@bb0590]). Dihydrotestosterone treatment induces polycystic ovary syndrome (PCOS) features in mature female rats ([@bb0165]). These include polycystic ovaries displaying unhealthy antral follicles, increased body fat, hypercholesteremia, anovulation, and acyclicity. Furthermore, elevated androgen levels in female rats have been demonstrated to impair glucose-stimulated insulin secretion, partly through the dysfunction of pancreatic β cell mitochondria ([@bb0800]). Chronic administration of estradiol has been shown to improve insulin sensitivity in rodents ([@bb0355]).

Effects of endogenous sex hormones {#s0015}
==================================

Sex hormone--binding globulin affects the bioavailable fraction of hormones and sequesters the actions of androgens and estrogens ([@bb4500]). Additionally, serum SHBG can directly affect cells by binding to its receptor and acting as a hormone ([@bb0640]). Low levels of SHBG have been associated with impaired glucose control, suggesting a link between SHBG and glucose regulation ([@bb0235], [@bb4500], [@bb0380], [@bb0520], [@bb0730]). Low SHBG and high free androgen index are significantly associated with cardiovascular risk factors ([@bb0730]). Furthermore, higher SHBG levels are associated with a reduced risk of MetS ([@bb0150]). Increases in SBGH after lifestyle interventions in postmenopausal women are associated with a favorable impact on fasting and postchallenge glucose levels ([@bb0430]).

Several observational studies have demonstrated that total and free T levels are higher in women with MetS ([@bb0150]). Additionally, higher T levels in women increase the risk of T2DM ([@bb0235]). Furthermore, the T/estradiol ratio and its rate of change during the menopausal transition increase the incidence of MetS ([@bb0755]). A vast number of studies indicate a critical and protective role for estrogen receptor alpha in the maintenance of metabolic homeostasis and insulin sensitivity ([@bb0355]). Estradiol and estrogen receptor alpha--specific agonists promote energy homeostasis; improve body fat distribution; and ameliorate IR, β cell function, and inflammation ([@bb0355]).

Effects of exogenous sex hormones {#s0020}
=================================

Menopausal hormone replacement therapy (HRT) has shown beneficial effects on women's metabolic profile in several studies ([@bb0510]). HRT was associated with a 20% diabetes risk reduction and improvement of insulin sensitivity ([@bb0525], [@bb0655]). In addition, HRT has been associated with lower levels of fasting glucose and total cholesterol (TC) and decreased systolic BP, body mass index (BMI), WC, and waist-to-hip ratio among both diabetic and nondiabetic women ([@bb0435]). Studies on postmenopausal HRT showed that oral estrogen increased HDL-C and TG and decreased low-density lipoprotein cholesterol (LDL-C) levels ([@bb0320], [@bb0560]). Estrogen-induced increases in HDL-C and TG were opposed according to the type of progestogen ([@bb0320]).

Metabolic syndrome through female life cycle {#s0025}
============================================

Features of MetS may begin in childhood and continue through adolescence ([@bb0340]). The prevalence of MetS in children is unknown because of a lack of diagnostic criteria in the pediatric population ([@bb0340], [@bb0810]). Factors such as obesity, IR, genetic predisposition, environment, and ethnic heritage may be involved in MetS development during childhood ([@bb0645]). Early menarche, especially among low-birth-weight females, increases the risk of MetS during young adulthood ([@bb0440], [@bb0505], [@bb0790]). In this population, high TG and low HDL-C levels are the most common MetS components ([@bb0020]). Puberty is associated with a 30% decrease in insulin sensitivity during the progression from Tanner stage II to IV ([@bb0060], [@bb0340]).

Pregnancy is characterized by increased physiologic requirements associated with a relative degree of IR and hyperlipidaemia, which catapults women into a metabolic state ([@bb0665], [@bb0790], [@bb0815]). These metabolic changes could be considered stress tests of maternal carbohydrate and lipid pathways and vascular function ([@bb0665]). The contribution of sex hormones to metabolic adaptations during pregnancy is supported by a body of literature (reviewed by [@bb0845]). Obesity during pregnancy increases the risk of gestational diabetes mellitus (GDM) and hypertension (HTN; [@bb0130], [@bb0330]). Women with MetS are at a higher risk for preeclampsia and GDM ([@bb0330]), and women with GDM are at a higher risk for T2DM and CVD later in life ([@bb0130], [@bb0185], [@bb0390], [@bb0815]). Preeclampsia is an additional risk factor for T2DM and CVD ([@bb0130]). Many studies have indicated a positive association between the number of children and a mother's later risk for CVD ([@bb0630]). However, parity and CVD risk might be affected by other socioeconomic and lifestyle factors ([@bb0630]).

Natural menopause is associated with an acceleration of risk of MetS independently of aging ([@bb0850]). Menopause is characterized by hormonal changes that substantially increase the risk for CVD and MetS. The onset of MetS during menopause is mainly due to a deficiency of estrogens, which exert a cardioprotective role ([@bb0790]). Furthermore, relative androgen excess during the menopausal transition is predictive of MetS ([@bb0755]). Elevated T and decreased SHBG levels are the most significant factors correlated to MetS in postmenopausal women ([@bb0850]).

Mechanisms underlying the skin: Metabolic syndrome connection {#s0030}
=============================================================

IR, hyperandrogenism, chronic inflammation, and oxidative stress are the main mechanisms that link skin disease to MetS. These mechanisms are involved in complex interactions; for example, the chronic inflammation that is often linked to obesity makes IR more likely to occur. Sex hormones have complex interactions with obesity, inflammation, and MetS ([@bb0645]). IR, possibly related to a postreceptor defect in adipose tissue, plays a paramount role in MetS.

Conditions associated with hyperandrogenism are shown in [Table 2](#tbl0010){ref-type="table"} ([@bb0170], [@bb0175], [@bb0415], [@bb0540], [@bb0555], [@bb0645], [@bb0675]). Acne is the most common manifestation of cutaneous hyperandrogenism ([@bb0200]). Other cutaneous manifestations include hirsutism, acanthosis nigricans (AN), female pattern alopecia (PA), and skin tags (STs) ([@bb0200], [@bb0645]). The clinical assessment of hyperandrogenism should be followed by a biochemical assessment (Meet et al., 2013). Of note, clinical features of cutaneous hyperandrogenism can be present without evidence of biochemical hyperandrogenism ([@bb0575]).Table 2Conditions associated with hyperandrogenismTable 2Idiopathic hyperandrogenismAdrenal dysfunctionCongenital adrenal hyperplasia (classical, nonclassical)Ovarian dysfunction (abnormal gonadal development, stromal hyperthecosis)Polycystic ovary syndromeHyperandrogenic insulin-resistant acanthosis nigricans syndromeCushing syndromeHyperprolactinemiaThyroid dysfunctionAcromegalyAndrogen-secreting tumor (ovarian or adrenal)Gestational hyperandrogenism (theca lutein cysts, luteomas)Exogenous androgenDrug-induced (e.g., cyclosporine, progestin, diazoxide, minoxidil, phenytoin)[^2]

Polycystic ovary syndrome {#s0035}
=========================

PCOS is the most common endocrine abnormality in women of reproductive age ([@bb0750]). Its prevalence among women of reproductive age is 6.5% to 8.0% per the National Institutes of Health 1990 criteria and increases to 15% to20% when the Rotterdam 2004 criteria are used ([@bb0325], [@bb0710]). The clinical features of PCOS include acne, hirsutism or less severe excessive hair growth, AN, alopecia, amenorrhea, oligomenorrhea or dysfunctional bleeding, anovulatory infertility, and central obesity ([@bb0575], [@bb0670]). The acne severity in women with PCOS is associated with higher total and free T levels and free androgen index value ([@bb0300]).

IR, combined with androgen excess and abnormal gonadotropic functions, plays a crucial role in the pathogenesis of PCOS ([@bb0035], [@bb0055], [@bb0470]). Insulin may increase androgen serum levels ([@bb0470]), and women with both PCOS and MetS tend to manifest hyperadrogenemia, lower serum SHBG levels, and AN more often than women who have PCOS alone ([@bb0065]). On the other hand, MetS shows a substantially higher prevalence (ranging from 8.2% in Italy to 43%-47% in the United States) in women with PCOS than in age-matched women in the general population ([@bb0170], [@bb0175], [@bb0240], [@bb0315]).

Dyslipidemia is often observed in women with PCOS who have low HDL-C, high LDL-C, and high TG levels ([@bb0230], [@bb0480]). Increased WC and low serum HDL-C levels are the most commonly documented components of MetS in women with PCOS ([@bb0240], [@bb0835]). Women with PCOS and MetS have higher values of BP, BMI, and ovarian size and increased levels of TG, TC, fasting blood sugar, and 2-hour blood sugar compared with women with PCOS but without MetS ([@bb0835]).

Obesity is reported in 61% to 76% of women with PCOS ([@bb0265]). Furthermore, obese individuals with PCOS have a worse metabolic profile than normal weight controls ([@bb0500]). Although not required for a diagnosis of PCOS, IR plays a prominent role in PCOS. Women with PCOS have an increased prevalence of impaired glucose tolerance and T2DM ([@bb0565]). IR in PCOS occurs independently of obesity, and lean women with PCOS were found to have a higher risk for CVD compared with healthy controls ([@bb0250], [@bb0255]). Asprosin, a newly discovered peptide, is associated with BMI, glucose metabolism, insulin homeostasis, and inflammation ([@bb0495]). Increased asprosin levels were associated with a higher possibility of having PCOS ([@bb0025]). A higher risk of HTN, especially among PCOS patients aged ≤40, has been shown ([@bb0135]).

The MetS/PCOS overlap significantly increases the risk of developing atherothrombosis and T2DM ([@bb0040], [@bb0215], [@bb0295]). Insulin-sensitizing agents, such as biguanide metformin, and lifestyle changes are beneficial in the treatment and prevention of metabolic abnormalities in women with PCOS ([@bb0295], [@bb0615]). Generally, the administration of oral contraceptives, the traditional pharmacological therapy for PCOS, leads to improved menstrual patterns and serum androgen levels compared with metformin, but metformin is more effective than oral contraceptives in reducing fasting insulin and lowering TG levels ([@bb0210]).

Psoriasis {#s0040}
=========

Psoriasis is increasingly recognized as a systemic inflammatory disorder ([@bb0735]). A number of studies have shown that the prevalence of MetS is higher among patients with psoriasis, both in pediatric and adult populations ([@bb0095], [@bb0335], [@bb0465]). The association between psoriasis and MetS is directly correlated with the severity of psoriasis ([@bb0465], [@bb0720]). Psoriasis is an independent factor for CVD ([@bb0735]). The severity of disease and nail pitting are risk factors of CVD (Gelfand et al., 2016; [@bb0720]). Risk factors for CVD occur with higher incidence in patients with psoriasis than in the general population ([@bb0410], [@bb0570]). The risk of myocardial infarction is significant even for patients with mild psoriasis ([@bb0095], [@bb0735]). Longer course of disease is associated with a greater risk for CVD ([@bb0100]), and women with psoriasis are at high risk for HTN ([@bb0620]). Furthermore, patients with psoriasis appear to have more difficult-to-control HTN compared with nonpsoriatic, hypertensive patients ([@bb0105], [@bb0745]).

Dyslipidemia has been associated with psoriasis; however, the directionality between these conditions remains unclear ([@bb0515], [@bb0735], [@bb0820]). Obesity is an independent factor for psoriasis, and the risk in women increases with a higher BMI score ([@bb0455], [@bb0465], [@bb0680]). Heterogeneous randomized weight loss clinical trials showed that patients who received weight loss interventions had a greater reduction in the severity of psoriasis when compared with controls ([@bb0775]). Lastly, weight loss in obese patients on biologic treatment showed an increase in drug efficacy ([@bb0050]). Obesity seems to favor psoriasis in predisposed individuals because of the proinflammatory state and release of mediators, such as adipokines that contribute to inflammation ([@bb0585]). Adiponectin, an antiinflammatory protein, is decreased among patients with psoriasis compared with healthy controls ([@bb0180], [@bb0400], [@bb0700], [@bb0805]).

Women with psoriasis are at increased risk of diabetes independently of their BMI ([@bb0620]). The likelihood of IR relates to psoriasis severity ([@bb0110], [@bb0465]). Additionally, diabetic patients with psoriasis are more likely to be under pharmacologic treatment and report vascular complications than diabetic patients without psoriasis ([@bb0090], [@bb0110], [@bb0740]).

Hidradenitis suppurativa {#s0045}
========================

Hidradenitis suppurativa (HS) is more prevalent in women than in men in the United States ([@bb0780]). Changes in HS activity have been reported during times of fluctuating hormones, such as during premenstrual periods, pregnancy, and menopause ([@bb0195], [@bb0635]). Estradiol and progesterone levels decline during the premenstrual period, and premenstrual HS flares occur in 44% of 63% of patients ([@bb0635]). The decline of estrogen and progesterone levels during menopause has been associated with a decline in HS symptoms and cases ([@bb0125], [@bb0160], [@bb0195]).

The role of androgens in HS remains unclear. Although there is no increase in serum androgen levels in most patients with HS, there is evidence supporting the efficacy of anti-androgen medications (i.e., spironolactone, finasteride, and dutasteride) in HS ([@bb0445], [@bb0420]). There is a lack of supportive data regarding the use of oral contraceptive pills for HS treatment ([@bb0195]).

The association of HS with MetS has been consistently identified in a number of studies ([@bb0650], [@bb0705], [@bb0765]). The relationship to MetS applies also to young HS patients and those with mild disease ([@bb0290]). IR is common among patients with HS ([@bb0785]). Compared with the general population, patients with HS are three times more likely to have diabetes ([@bb0155]) and are more likely to have hyperlipidemia, obesity, and/or HTN ([@bb0695]). Patients with HS are also at an increased risk for myocardial infarction, ischemic stroke, CDV-associated death, and all-cause mortality ([@bb0260]). The severity of HS is a risk factor for CVD ([@bb0720]). Mean resting heart rate, a risk factor for CVD, is higher in patients with severe HS compared with healthy individuals ([@bb0375]).

Acrochordons {#s0050}
============

Acrochordons, or STs, are more common among overweight individuals and may be a marker of MetS ([@bb0270], [@bb0685]). STs have been associated with impaired insulin homeostasis (i.e., glucose intolerance and diabetes; [@bb0140], [@bb0530], [@bb0660]) and hypercholesterolemia ([@bb0610]). A recent study demonstrated that the lipid profile of patients with STs is characterized by high levels of LDL-C, TC, and TG, but the mean HDL-C level was lower ([@bb0685]). Individuals with STs have higher systolic and diastolic BP than controls ([@bb0685]). The number and presence of mixed-colored STs has been related to obesity ([@bb0275]). Serum leptin levels are higher in patients with STs than in controls ([@bb0795]). Although the pathophysiologic mechanism by which leptin is related to STs is unknown, the mitogenic effect of leptin on keratinocytes may be involved ([@bb0715]).

Acanthosis nigricans {#s0055}
====================

AN is linked to obesity, PCOS, T2DM, and IR ([@bb0360]). Hyperinsulinemia is associated independently with AN; it leads to the stimulation of epidermal keratinocytes, producing the characteristic lesions that are most commonly noted in skin folds ([@bb0645], [@bb0725]). This link appears to start early, and a systematic review demonstrated the relationship between AN and IR/T2DM in children with obesity ([@bb0005]). Periorbital pigmentation in a female patient with AN was proposed as an alarming sign of MetS ([@bb0840]).

Acne vulgaris {#s0060}
=============

Pathogenetic mechanisms involved in the development of acne, including excess sebum production, release of inflammatory mediators, and follicular keratinization, are affected by excess androgen activity ([@bb0145], [@bb0115]). The activation of mammalian target of rapamycin complex 1 signaling is involved in both acne pathogenesis and IR ([@bb0545]). Acne in women has been linked with IR and lipid profile alterations independent of hyperandrogenism ([@bb0285], [@bb0385]). Nonetheless acne has not been established as a prognostic factor for MetS ([@bb0645]).

Rosacea {#s0065}
=======

Studies have linked rosacea to risk factors for CVD ([@bb0015], [@bb0245]). Patients with rosacea have higher TC, LDL-C, and C-reactive protein levels than controls ([@bb0015], [@bb0245]). Furthermore, patients with rosacea are also more likely to report a family history of CVD ([@bb0245]). IR and elevations in systolic and diastolic BP are significantly associated with rosacea ([@bb0015]). Furthermore, dysregulation of sympathetic system and T effect may be involved in cases of rosacea linked to MetS ([@bb0485]).

Female pattern alopecia {#s0070}
=======================

PA in women has been linked to MetS, and the severity of the condition is associated with CVD ([@bb0720]). A population-based survey shopwed that female patients with PA are more likely to have CVD, dyslipidemia and obesity ([@bb0425]). Among MetS traits, WC and HTN are the most important factors associated with PA ([@bb0280]). Furthermore, WC increases with the severity of PA ([@bb0280]). Women with PA have higher TG, LDL-C, and TC levels and lower HDL-C levels than nonalopecic controls ([@bb0075], [@bb0085], [@bb0120]). Hyperglycemia or diabetes was more common among patients with alopecia ([@bb0070], [@bb0080]). A relationship with IR ([@bb0535]) has been disputed ([@bb4000]). Additionally, patients with hyperglycemia and alopecia have significantly lower SHBG levels than individuals with hyperglycemia.

Hirsutism {#s0075}
=========

Hirsutism in women is defined as excessive hair growth in androgen-dependent areas ([@bb0550]). Hirsutism results from an interaction between androgen and hair follicle sensitivity to this sex hormone ([@bb0555]). Idiopathic hirsutism is the most common form, but the condition can be associated with PCOS or medication ([@bb0770], [@bb0555]). Hirsutism is associated with IR and increased prevalence of impaired glucose tolerance in obese patients ([@bb0770]).

Systemic lupus erythematosus {#s0080}
============================

Systemic lupus erythematosus (SLE) shows a female predilection. Women with SLE have a greater than five-fold risk for coronary artery disease events ([@bb0600]). The risk of MetS is significantly higher in patients with SLE compared with healthy controls ([@bb0345]). Among MetS components, elevated TG levels and HTN were the most strongly linked to SLE ([@bb0345]).

Miscellaneous conditions {#s0085}
========================

Lichen planus has been associated with MetS, and the MetS criteria most frequently reported in patients with lichen planus are elevated TG, WC, and low HDL-C levels ([@bb0070], [@bb0080]). Atopic dermatitis is possibly related to MetS, and female sex was suggested as a risk factor ([@bb0310]). In a study, women with squamous cell carcinoma had a tendency toward increased glucose and TG levels ([@bb4100]). Another study indicated that seborrheic dermatitis is a predictive factor for MetS ([@bb0370]).

Xanthelasma palpebrum (XP) appears predominantly in middle-aged women ([@bb0405]). Significantly elevated mean TC and TG levels, very low density lipoprotein levels, and low HDL-C values in patients with XP compared with controls have been reported ([@bb0405]). XP may be a marker of atherosclerosis irrespective of lesion size or serum lipid levels ([@bb0595]). However, Ozdöl et al. found that hyperlipidemia was significantly more common in patients with XP than in the control group, but there was no increase in the observed risk of CVD ([@bb0580]). The prevalence of MetS in XP has not been adequately studied, and the risk for CVD requires further investigation.

Conclusion {#s0090}
==========

The constellation of MetS, IR, and CVD can be present in a wide spectrum of cutaneous conditions. The health care provider should be familiar with skin diseases associated with MetS and promptly recognize MetS-relevant comorbidities, such as CVD in patients with these skin diseases. Establishing an early diagnosis of MetS is crucial to management and facilitates counseling that may include lifestyle interventions. IR and dyslipidemia should be managed, and tighter glycemic control and HTN screening should be pursued. A multidisciplinary approach is required to address the multifaceted aspects of MetS linked to skin disease.
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==============================
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